As per MRFR analysis, the US Heart Failure POC and LOC Devices Market Size was estimated at 14.72 (USD Million) in 2023. The US Heart Failure POC and LOC Devices Market Industry is expected to grow from 17.15(USD Million) in 2024 to 96 (USD Million) by 2035. The US Heart Failure POC and LOC Devices Market CAGR (growth rate) is expected to be around 16.95% during the forecast period (2025 - 2035).
The US Heart Failure POC (Point-of-Care) and LOC (Laboratory-Optimized Care) Devices Market is currently witnessing significant trends driven by the increasing prevalence of heart failure in the country. The aging population, along with rising obesity rates, contributes to the growing demand for effective heart failure management tools. As per the US Centers for Disease Control and Prevention (CDC), millions of Americans are living with heart failure, pushing healthcare providers to adopt innovative solutions for monitoring and treating this condition. Technological advancements in the devices, including real-time monitoring and remote patient management capabilities, are becoming crucial market drivers. Moreover, there is a major opportunity to enhance patient outcomes through the development of portable and user-friendly devices that facilitate easier home care. The rise of telehealth has also opened new avenues for heart failure monitoring, as patients are now able to receive care remotely, aligning with trends toward increased patient engagement and personalized healthcare. Recent innovations in biosensors and wearable technology are creating exciting opportunities to improve the accuracy of heart failure diagnosis and management. Additionally, regulatory support from bodies like the Food and Drug Administration (FDA) for expedited approval of novel heart failure devices is influencing market dynamics positively.With the focus on cost-effective healthcare solutions, the integration of artificial intelligence in these devices is emerging as a vital trend, allowing for predictive analytics to better manage patient outcomes. Overall, the US Heart Failure POC and LOC Devices Market is evolving rapidly, driven by technological advancements and the growing need for effective management of this complex condition.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of heart failure in the United States is a significant driver for the US Heart Failure Point of Care (POC) and Laboratory Onsite Testing (LOC) Devices Market Industry. According to the American Heart Association, about 6.2 million adults in the US have heart failure, and this number is projected to rise due to the aging population and increasing rates of hypertension and diabetes. The Centers for Disease Control and Prevention reports that the number of adults with diagnosed heart failure has increased by over 20 percent in the last decade, necessitating advanced monitoring and diagnostic devices to manage this condition effectively.This growing patient base drives demand for innovative POC and LOC devices that can facilitate timely and accurate management of heart failure, thus significantly contributing to the market growth. Major companies like Abbott Laboratories and Medtronic are at the forefront of developing these technologies, further pushing the market forward as they release new products to cater to this rising need.
Technological advancements play a crucial role in the expansion of the US Heart Failure POC and LOC Devices Market Industry. Innovations such as miniaturization of devices, integration of Artificial Intelligence, and enhanced connectivity options like Bluetooth and mobile health applications are transforming the landscape of heart failure management. According to the Food and Drug Administration, from 2018 to 2022, there has been a significant increase in the approval of novel cardiac monitoring devices, which enhances real-time data collection and patient care.This trend is bolstered by advancements made by established firms such as Philips Healthcare, which has invested heavily in Research and Development to create next-generation monitoring devices that provide better outcomes and patient experiences. These enhanced capabilities are critical in a market that seeks efficiency and effectiveness in managing heart failure.
Increased awareness of heart failure and its management among both healthcare professionals and the general public is another vital driver for the US Heart Failure POC and LOC Devices Market Industry. Major educational campaigns launched by organizations like the American Heart Association and ongoing training programs for healthcare practitioners have significantly improved the understanding of heart failure. As reported, the National Heart, Lung, and Blood Institute noted that community health initiatives have led to an approximate 15 percent increase in screenings and early detection of heart failure.This rise in awareness directly correlates with more patients seeking out advanced monitoring solutions, driving the demand for POC and LOC devices. Organizations like Boston Scientific also contribute by distributing educational resources, which help create a well-informed patient population willing to invest in innovative medical technologies.
The Test Type segment within the US Heart Failure POC and LOC Devices Market is increasingly recognized for its pivotal role in advancing cardiac care through innovative testing methodologies. This segment encapsulates various testing approaches, notably Proteomic Testing, Metabolomic Testing, and Genomic Testing, each contributing uniquely to the early detection and management of heart failure. Proteomic Testing is particularly significant as it focuses on the analysis of proteins in the blood, offering insights into the underlying biological processes of heart failure, enabling clinicians to tailor treatment strategies effectively.Metabolomic Testing complements this by examining metabolic profiles, which can reflect physiological changes in heart function, thus helping in identifying at-risk patients who might benefit from proactive interventions. Genomic Testing, on the other hand, delves into the genetic makeup of individuals, highlighting hereditary factors that could predispose patients to heart failure, facilitating personalized medicine approaches. Collectively, these testing types not only enhance patient outcomes but also drive innovations in the US Heart Failure POC and LOC Devices Market.As the need for more accurate and rapid tests increases, the integration of these testing methods represents a transformative opportunity for healthcare providers to improve patient management and develop targeted therapeutics, reinforcing their essential role in the ongoing battle against heart failure. The interplay of these testing modalities is set to support a robust growth trajectory, aligning with the increasing emphasis on precision medicine in the United States. The demand for advanced testing technologies continues to rise as healthcare systems strive to implement more efficient diagnostic pathways, ultimately aiming to enhance the quality of life for individuals living with heart failure.The Test Type segment stands as a critical component in achieving these goals, with a substantial contribution to the broader landscape of heart failure management strategies, driven by ongoing research, technological advancements, and a focus on improving patient care outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Technology segment of the US Heart Failure Point of Care (POC) and Laboratory of Care (LOC) Devices Market encompasses advanced systems that are driving significant innovations in heart failure management. Microfluidics technology is particularly vital as it allows for rapid and efficient analysis of minute fluid samples, enabling healthcare professionals to make quick diagnostic decisions. This technology enhances patient outcomes by facilitating timely interventions, thus improving the overall management of heart failure. Meanwhile, Array-based Systems are gaining traction for their ability to process multiple tests simultaneously, making them crucial for comprehensive monitoring and diagnosis.Both technologies are essential for advancing treatment methodologies, as they support personalized healthcare approaches tailored to individual patient needs. Moreover, the increasing incidence of heart failure in the US highlights the growing demand for these technologies, presenting opportunities for further developments and improved accessibility, ultimately fostering market growth within this segment.
The US Heart Failure POC and LOC Devices Market is experiencing notable growth driven by various end user segments, which play a crucial role in shaping the market landscape. Hospitals and clinics remain vital as they provide acute care and advanced monitoring for heart failure patients, leveraging cutting-edge devices to manage conditions effectively. Homecare services have gained traction due to the rising preference for at-home healthcare, allowing patients to receive continual monitoring and treatment in a more comfortable setting, thereby potentially reducing hospitalization rates.Specialty centers, focusing on specific cardiac conditions, play a significant role by offering specialized care and utilizing advanced technology to enhance patient outcomes. Other channels also contribute to the market by catering to diverse healthcare needs and settings. The growth of telehealth solutions and wearable technologies further supports these end user segments by enabling remote patient monitoring, thus improving accessibility and convenience in managing heart failure. Overall, these segments collectively reflect the increasing demand for innovative heart failure management solutions in the US healthcare system, improving the quality of life for patients while addressing the challenges posed by this chronic condition.
The competitive landscape of the US Heart Failure Point of Care (POC) and Laboratory of Care (LOC) Devices Market is characterized by rapid innovation and a growing demand for effective cardiac care solutions. As heart failure remains a leading cause of morbidity and mortality in the United States, the market has experienced significant expansion, driven by advancements in technology and heightened focus on patient-centric solutions. Diverse players are engaging in strategic collaborations, product launches, and investments aimed at enhancing their offerings and capturing market share. The competition includes established medical device manufacturers as well as emerging companies specializing in novel therapies and diagnostic tools tailored for heart failure management. The dynamic nature of this market underscores the importance of understanding competitive strategies and positioning to navigate the evolving landscape successfully.
LivaNova has established a strong presence in the US Heart Failure POC and LOC Devices Market, leveraging its technological innovations and well-regarded expertise in medical devices. The company's strengths lie in its significant investment in research and development, which has led to the creation of advanced devices that cater to the needs of heart failure patients. With a focus on optimizing patient outcomes, LivaNova has developed comprehensive solutions that support both acute and chronic heart failure management, enriching its competitive advantage in an increasingly crowded marketplace. The company's commitment to enhancing accessibility and efficiency in cardiac care further positions it favorably, allowing it to foster lasting relationships with healthcare providers and patients alike.
AtriCure operates in the US Heart Failure POC and LOC Devices Market with a commitment to delivering comprehensive solutions for cardiac arrhythmias and heart failure. The company offers a range of innovative products, including radiofrequency ablation technology and advanced surgical devices, specifically designed to improve outcomes for patients suffering from heart failure. AtriCure’s strong market presence is bolstered by its relentless pursuit of innovation and focus on education in the medical community, helping drive adoption of its technologies. In recent years, AtriCure has engaged in strategic mergers and acquisitions to expand its portfolio, enhance its product offerings, and penetrate the market more effectively. This proactive approach, combined with a dedication to clinical research and collaboration with key healthcare stakeholders, positions AtriCure as a formidable player in the US market, with its strengths firmly aligned with addressing the evolving challenges of heart failure care.
In recent months, the US Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market has witnessed significant developments with companies such as Medtronic, Abbott Laboratories, and Boston Scientific leading innovations aimed at enhancing patient care and monitoring. Notably, in October 2023, Medtronic announced advancements in its heart failure monitoring technology, contributing to improved patient outcomes and streamlined clinical workflows. Abbott Laboratories has also invested in research to expand its cardiac device portfolio, addressing the growing demand for efficient heart failure management solutions. Over the past two years, there have been notable market expansions, with LivaNova and ZOLL Medical increasing their product availability to cater to rising patient populations. In March 2023, a strategic collaboration between Biotronik and Cleveland HeartLab was announced to enhance diagnostic capabilities for heart failure patients, reflecting a trend towards partnerships for technological advancements in this area. Additionally, the market witnessed a significant upsurge driven by the increasing prevalence of heart conditions and a rising focus on early diagnosis, emphasizing the importance of POC and LOC devices in modern healthcare practices in the US.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 14.72(USD Million) |
| MARKET SIZE 2024 | 17.15(USD Million) |
| MARKET SIZE 2035 | 96.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.95% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | LivaNova, AtriCure, ZOLL Medical, Hewlett Packard, EDAN Instruments, Medtronic, Abbott Laboratories, Boston Scientific, Cardinal Health, Biotronik, Philips, Terumo, Sorin Group, Johnson and Johnson, Cleveland HeartLab |
| SEGMENTS COVERED | Test Type, Technology, End User |
| KEY MARKET OPPORTUNITIES | Remote patient monitoring solutions, Advanced telehealth integration, Wearable heart monitoring devices, Real-time data analytics tools, Personalized treatment platforms |
| KEY MARKET DYNAMICS | Aging population prevalence, Advancements in technology, Rising healthcare expenditure, Increasing prevalence of heart disease, Focus on early diagnosis |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
In 2024, the US Heart Failure POC and LOC Devices Market is expected to be valued at 17.15 million USD.
By 2035, the market is projected to reach a value of 96.0 million USD.
The expected CAGR for the market from 2025 to 2035 is 16.95%.
Proteomic Testing is projected to be a significant segment, valued at 5.0 million USD in 2024 and expected to grow to 28.0 million USD by 2035.
The Metabolomic Testing segment is expected to grow from 6.45 million USD in 2024 to 37.0 million USD by 2035.
Significant players such as LivaNova, AtriCure, and Medtronic are major contributors to the market landscape.
The Genomic Testing segment is expected to grow from 5.7 million USD in 2024 to 31.0 million USD by 2035.
Growing awareness of heart failure and technological advancements in diagnostic devices are key growth drivers.
Challenges include regulatory hurdles and the need for continuous innovation in device technology.
The current economic conditions are expected to create both opportunities and challenges for market growth and investment.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
